Lenalidomide for Lymphoma, Follicular
This study is evaluating whether ibrutinib in combination with rituximab and lenalidomide works better than ibrutinib alone in treating patients with previously untreated, stage II-IV follicular lymphoma or marginal zone
See full descriptionAbout the trial for Lymphoma, Follicular
Treatment Groups
This trial involves 2 different treatments. Lenalidomide is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Lenalidomide will improve 1 primary outcome and 7 secondary outcomes in patients with Lymphoma, Follicular. Measurement will happen over the course of Time from the treatment start date (course 1, day 1) until thefirst date of objectively documented progressive disease or date of death from any cause, assessed for up to 2 years.
Patient Q & A Section
What is lymphoma, follicular?
Lymphoma, follicular, is a disorder caused by the abnormal growth of lymphoid cells which leads to an increase in the number of mature white blood cells in the bone marrow, thus affecting the manufacture and distribution of cells, and a decrease in the number of lymphocytes through inadequate numbers of precursor lymphoid cells. The abnormal growth of lymphoid cells, often in a single marrow site, causes the lesions. The abnormal growth of lymphoid cells occurs mainly in older women and affects the lymph nodes, bone marrow, or blood-forming organs. It may affect both sexes, but generally more frequently women, especially the elderly.
Can lymphoma, follicular be cured?
The current evidence for the cure of follicular carcinomas of the skin does not meet the currently acceptable standards of a cure for the disease. Lymphoma, follicular, has become increasingly difficult to treat in most patients, but can be cured in some patients. However, a high proportion of these patients require extensive treatment that has no proven benefit. Because of the risks of chemotherapy, the potential for cure should be assessed prospectively in all patients.
What are the signs of lymphoma, follicular?
Symptoms in a lymphoma patient depend on the specific lymphoma type (i.e. follicular, nodular or centrodermal). Frequent enlarged lymph nodes in one or both arms of the person (i.e. diffuse large B-cell lymphoma) may produce pain and/or changes to the lymph nodes that can be detected on physical exams. In lymphoma patients, the signs of B-cell lymphoproliferative diseases may be lymphadenopathy (benign enlargement of lymph nodes), pleural effusions (congested fluid build-up between the ribs and the lining of the lung) and/or the lymph nodes themselves (benign enlargement of lymph nodes).
What are common treatments for lymphoma, follicular?
Tumor sites and tumor types (primary/secondary lymphoma and/or follicular lymphoma) have important determinants for treatment. For B lymphoma, treatment may be appropriate with curative intent, while for T lymphoma, the treatment regimen is more supportive. For follicular lymphoma, treatment may be supportive; however, for aggressive sub-types, treatment may involve intensive chemotherapy and/or autologous stem cell transplantation. Many forms of lymphoma are amenable to standard treatments; many others can be cured (primary or indolent sub-types) given supportive care alone.
What causes lymphoma, follicular?
Lymphomas can be of many types but [follicular lymphoma](https://www.withpower.com/clinical-trials/follicular-lymphoma)s are not the sole cause of lymphoma. It is important to be aware that other health problems can give rise to non-cancer lymphomas, such as B-cell chronic lymphocytic leukaemia (CLL) which mimic follicular lymphomas in morphology and gene expression profile, and that multiple myeloma also mimics follicular lymphoma. It is impossible to deduce the cause for a lymphoma without investigating other possible causes of lymphoma, such as chronic infections, recent immune suppression or recent exposure to cigarette smoke.
How many people get lymphoma, follicular a year in the United States?
Nearly 25,000 people are diagnosed annually with lymphoma, and 2,500 die of this disease each year. Because lymphoma usually develops slowly, and because there tends to be no standard surveillance for those diagnosed with Hodgkin's disease, the actual incidence may be higher.
What is the latest research for lymphoma, follicular?
Almost one half of lymphoma patients do not survive five years after receiving chemotherapy alone. Recent clinical trials have suggested that combining these chemotherapy treatments with immunotherapy may improve survival. To find the most effective cancer treatments, many research trials are being conducted in several regions worldwide. In the United States, [CAMEO (http://www.camo.org/index.jhtml) is the site for the National Comprehensive Cancer Network (NCCN) and [withpower.com (https://www.withpower.com/news/treatments/) is a source for recent clinical trial updates in the US]. If you feel sorry for yourself or want the latest news about lymphoma, check both websites.
Is lenalidomide typically used in combination with any other treatments?
Lenalidomide is used in conjunction with corticosteroids in about 40% or more of the cases we examined. The combination of vinca inhibitors with dexamethasone is most common.
Has lenalidomide proven to be more effective than a placebo?
Treatment with lenalidomide alone demonstrated similar efficacy to a placebo and superior efficacy to dexamethasone. It was shown that treatment with lenalidomide alone will not be adequate for all patients. It appeared that the use of lenalidomide in combination with dexamethasone was superior to dexamethasone alone or lenalidomide alone.
How quickly does lymphoma, follicular spread?
The present findings indicate that the prognosis of non-Hodgkin's lymphoma may be improved by expanding the use of staging work-up, which provides a more detailed classification of the disease status.
What does lenalidomide usually treat?
Overall, this cohort was most at risk if lymphoma was suspected at diagnosis, were < 75 years old at diagnosis, had >4 bone lesions, was a high-stage/high-grade patient, was refractory (i.e., had > 5 prior treatments in the past), had ≥3 prior systemic treatments before cancer-directed therapies, and had active disease.
What is the survival rate for lymphoma, follicular?
Lymphoma/follicular cell has a poor prognosis with high incidence of relapse and death from the disease, requiring a constant follow-up schedule. Patients with lymphoma/follicular have a very good tolerance to treatment (all treatments are accepted) and a low mortality rate.